For many people, the biotech industry and global health community might seem like strange bedfellows. One is driven by commercial success, the other largely by philanthropy. Innovation is key, however, for both fields, and the Washington, DC–based not-for-profit BIO Ventures for Global Health (BVGH) is trying to draw on that commonality. Melinda Moree, who officially became BVGH’s chief executive at the start of this year, has experience bringing new technologies to the poorest and unhealthiest of communities. A former director of the Malaria Vaccine Initiative, Moree oversaw a successful proof-of-concept study for a malaria vaccine. Christian Torres spoke with Moree about how BVGH engenders partnerships between biotech and global health and how it might produce the next big achievement for both. (Click here to continue reading)

Image courtesy Jeff Mauritzen